Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017
Entire Document
 


Slide 20

Phase 1b study patient demographics Characteristic Statistic (Placebo/ Placebo) (N = 11) (Vancomycin / SER-287 daily) (N = 15) (Placebo/SER-287 weekly) (N = 15) (Vancomycin / SER-287 weekly) (N = 17) Ser-287 (N = 47) Overall (N = 58) Age (years) n 11 15 15 17 47 58   Mean (SD) 45.8 (15.20) 47.8 (18.59) 46.5 (16.12) 47.9 (11.18) 47.4 (15.10) 47.1 (15.00) Sex               Male n (%) 4 (36.4) 7 (46.7) 6 (40.0) 10 (58.8) 23 (48.9) 27 (46.6) Female n (%) 7 (63.6) 8 (53.3) 9 (60.0) 7 (41.2) 24 (51.1) 31 (53.4) Race               White n (%) 8 (72.7) 12 (80.0) 12 (80.0) 15 (88.2) 39 (83.0) 47 (81.0) Asian n (%) 1 (9.1) 0 0 1 (5.9) 1 (2.1) 2 (3.4) Black or African American n (%) 1 (9.1) 2 (13.3) 3 (20.0) 1 (5.9) 6 (12.8) 7 (12.1) Other - Indian n (%) 1 (9.1) 1 (6.7) 0 0 1 (2.1) 2 (3.4) Severity of UC               Mild n (%) 3 (27.3) 6 (40.0) 6 (40.0) 9 (52.9) 21 (44.7) 24 (41.4) Moderate n (%) 8 (72.7) 9 (60.0) 9 (60.0) 7 (41.2) 25 (53.2) 33 (56.9) Receiving Current UC Treatment Prior to or On Date of 1st Pretreatment Dose               No n (%) 1 (9.1) 3 (20.0) 2 (13.3) 6 (35.3) 11 (23.4) 12 (20.7) 5-ASA n (%) 7 (63.6) 11 (73.3) 11 (73.3) 9 (52.9) 31 (66.0) 38 (65.5) Immunomodulator n (%) 2 (18.2) 1 (6.7) 4 (26.7) 2 (11.8) 7 (14.9) 9 (15.5) Steroid n (%) 3 (27.3) 3 (20.0) 2 (13.3) 0 5 (10.6) 8 (13.8) Other n (%) 1 (9.1) 0 0 1 (5.9) 1 (2.1) 2 (3.4) Time since first UC diagnosis (months) n 11 15 15 17 47 58   Mean (SD) 138.2 (85.91) 152.9 (143.77) 149.1 (141.34) 142.1 (105.41) 147.8 (127.51) 146.0 (120.12)


© Seres Therapeutics. All Rights Reserved.